Keywords: cor, integrilin, in-hospital, cost, reopro, recent, study
COR's Integrilin: "14% less in-hospital cost" than J&J's ReoPro
Article | 23 March 2000
A recent study has demonstrated that COR Therapeutics' Integrilin(eptifibatide) was associated with a 14% less in-hospital total cost than Johnson & ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
